Elbit Imaging Announces the Results of Its Annual General Meeting of Shareholders Held on October 13, 2016
October 13 2016 - 11:11AM
Elbit Imaging Ltd. (“EI” or the
“Company”) (TASE:EMITF) (NASDAQ:EMITF) announced
today that at its Annual General Meeting of Shareholders (the
"
Meeting") held on October 13, 2016, at the
Company's offices in Petah Tiqva, the following resolutions
described in the Proxy Statement to the Shareholders dated
6.9.2016 (the "
Proxy") and detailed
hereunder, were approved by the required majority:
- An amendment to the Company's compensation policy for directors
and officers.
- The terms of office and employment of Mr. Ron Hadassi as the
Company’s Chairman of the Board of Directors.
- Engagement in a Consultancy Agreement with a Company's
Director, Mr. Boaz Lifschitz.
- That Messrs. Alon Bachar, Ron Hadassi, Boaz Lifschitz, Nadav
Livni and Zvi Tropp are elected as directors of the Company until
the close of next Shareholder's Annual General Meeting of the
Company.
- Approve the compensation for each of the Company's non-external
directors, other than the Chairman, Mr. Ron Hadassi.
- That the Company's independent auditor, Brightman Almagor Zohar
& Co., a member of Deloitte, is appointed as independent
auditor of the Company for the fiscal year 2016 and until the close
of next Shareholder's Annual General Meeting of the Company.
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following
principal fields of business: (i) Commercial centers - initiation,
construction, and sale of commercial centers and other mixed-use
property projects, predominantly in the retail sector, located in
Central and Eastern Europe. In certain circumstances and depending
on market conditions, the Group operates and manages commercial
centers prior to their sale. (ii) Hotel - operation and
management of the Radisson hotel Complex in Bucharest, Romania.
(iii) Medical industries and devices - (a) research and
development, production and marketing of magnetic resonance imaging
guided focused ultrasound treatment equipment, and (b) development
of stem cell population expansion technologies and stem cell
therapy products for transplantation and regenerative medicine.
(iv) Plots in India - plots designated for sale initially
designated to residential projects.
Any forward-looking statements in our releases
include statements regarding the intent, belief or current
expectations of Elbit Imaging Ltd. and our management about our
business, financial condition, results of operations, and its
relationship with its employees and the condition of our
properties. Words such as “believe,” “expect,” “intend,” “estimate”
and similar expressions are intended to identify forward-looking
statements but are not the exclusive means of identifying such
statements. Actual results may differ materially from those
projected, expressed or implied in the forward-looking statements
as a result of various factors including, without limitation, a
change in market conditions, a decision to deploy the cash for
other business opportunities and the factors set forth in our
filings with the Securities and Exchange Commission including,
without limitation, Item 3.D of our annual report on Form 20-F for
the fiscal year ended December 31, 2015, under the caption “Risk
Factors.” Any forward-looking statements contained in our releases
speak only as of the date of such release, and we caution existing
and prospective investors not to place undue reliance on such
statements. Such forward-looking statements do not purport to be
predictions of future events or circumstances, and therefore, there
can be no assurance that any forward-looking statement contained in
our releases will prove to be accurate. We undertake no obligation
to update or revise any forward-looking statements.
For Further Information:
Company Contact
Ron Hadassi
Chairman of the Board of Directors
Tel: +972-3-608-6048
Fax: +972-3-608-6050
ron@elbitimaging.com
Elbit Imaging (CE) (USOTC:EMITF)
Historical Stock Chart
From Aug 2024 to Sep 2024
Elbit Imaging (CE) (USOTC:EMITF)
Historical Stock Chart
From Sep 2023 to Sep 2024